News
Aldeyra Therapeutics
ALDX · NASDAQ
$0.7343+$0.0692 (+10.40%)TodayMarket closed ·
Prev close $0.6651
Latest news
- NewsVandana Singh
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
- Press releaseBusiness Wire
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
- Press releaseBusiness Wire
Aldeyra Therapeutics to Host Regulatory Update Webcast
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
- Press releaseBusiness Wire
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Press releaseBusiness Wire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releaseBusiness Wire
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
- Press releasePRNewswire
ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
- Press releasePRNewswire
Aldeyra Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ALDX
- Press releaseGlobe Newswire
ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
- Press releasePRNewswire
ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
- Press releasePRNewswire
ALDX Deadline: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
- Press releasePRNewswire
ALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
- Press releasePRNewswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Submitted Incomplete Disclosures: SueWallSt
- Press releaseGlobe Newswire
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Aldeyra Therapeutics, Inc.
- Press releasePRNewswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
- Press releasePRNewswire
ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
- Press releasePRNewswire
ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
- Press releasePRNewswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executive Allegedly Approved Misleading Disclosures: Levi & Korsinsky
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
- Press releasePRNewswire
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
- Press releasePRNewswire
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Clinical Trial Results: SueWallSt
- Press releasePRNewswire
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsVandana Singh
What's Going On With Aldeyra Therapeutics Stock On Thursday?
- Press releaseGlobe Newswire
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
- Press releasePRNewswire
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsVandana Singh
FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68%
- NewsAvi Kapoor
Crude Oil Gains Around 2%; Elbit Systems Shares Jump On Upbeat Earnings
- NewsAvi Kapoor
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings
- Press releaseBusiness Wire
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsVandana Singh
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug
- NewsAvi Kapoor
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.